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Streptococcus pneumoniae (Pneumococcus) is a major cause of life 
threatening diseases including pneumonia, sepsis and meningitis. It causes 
about 500 thousands deaths per year in under-5 children. It is a Gram-positive 
bacterium with polysaccharide capsule. The capsule determines its serotype 
and the protective immunity is serotype specific. There are 94 serotypes and 
till today only 13-valent conjugate vaccine (PCV13) is available for 
immunization in children. Serotyping by conventional method (culture and 
serotyping) is expensive, time consuming and insensitive. As prevalence of 
serotypes of pneumococcus varies both geographically and temporally, 
continuous surveillance is necessary, both in pre and post vaccine period. 
Non-vaccine serotypes have emerged in the USA after introduction of 7-valent 
vaccine (PCV7) in the year 2000.  Though the presence of multiple serotype 
colonization has been reported, its role in a clinical outcome and emergence 
of non-vaccine serotype has not been clear.  
 
Although various PCR based methods have been developed to replace the 
conventional method of serotyping, a high throughput sensitive and 
quantitative method was in need to meet the demand of epidemiological 
survey and to detect the minor population of the bacteria in the multiple 
serotype colonization. We have developed a nanofluidic real-time PCR 
system, which can detect 50 serotypes in 29 groups, including all serotypes of 
the 13-valent-conjugate vaccine (PCV13) and the 23-valent-polysaccharide 
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vaccine (PPV).  The lower limit of detection was 30-300 copies per reaction. 
Minor population in the multiple serotypes, 1 in 1000 was easily detected. We 
have validated this assay with the conventional culture and serotyping. 
 
We applied this assay in nasopharyngeal samples from ARI (Acute 
Respiratory Infection) cases and healthy children in Vietnam. We found a 
positive correlation of serotypes/serogroups specific bacterial load with 
serotype/serogroup prevalence. This implied that higher bacterial load of a 
serotype in the nasopharynx might be an attributable factor for higher 
transmission of the serotype among host so that it could maintain higher 
prevalence. Another finding was the association of multiple serotype of co-
colonization with acute respiratory infections and dominance of one serotype 
over other in multiple serotype co-colonizations. This showed that the link of 
multiple serotypes with increased pathogenicity and competition among 
























Streptococcus pneumoniae is a common cause of death in under-5 children in 
world [1]. This Gram-positive bacterium is encapsulated with the 
polysaccharide capsule, which is the major virulent factor for evading the host 
immune response. The capsule also determines the serotypes of 
pneumococcus. As protective immunity is serotype specific and distribution of 
pneumococcal serotypes vary both geographically and temporally, the efficacy 
of pneumococcal conjugate vaccines (PCV7, PCV10, PCV13) is not 
consistent in all over the world [2]. Moreover, there is emergence of non-
vaccine serotypes of pneumococcus in places where the conjugated vaccines 
have been introduced, which has been a global concern [3].  
 
Conventionally identification of serotypes of pneumococcus is done by 
bacterial culture and serotyping, which is expensive, labour-intensive and less 
sensitive especially when antibiotics are taken by the patients prior to sample 
collection. To overcome these drawbacks of the conventional method of 
serotyping, various molecular methods have been developed and assays 
based on real-time PCR are promising as they are more sensitive than 
multiplex PCRs and provides quantitative data [4-6]. The sensitivity of the 
assay to detect minor population of subdominant serotypes in multiple 
serotypes have become important as multiple serotypes have been thought to 
be involved in vaccine serotype replacement, carriage detection and 
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pneumonia diagnosis [7]. In addition, the assay should provide the 
quantitative data of serotypes, as they would be helpful to understand the 
complex epidemiology of multiple serotypes. To meet these technical 
challenges and be applicable in a large-scale epidemiological study, a highly 
sensitive, specific and high-throughput molecular assay was in need.  
 
The antigenic structure of capsule polysaccharide chain of the pneumococcus 
is determined by a series of glycosyltransferases encoded by the cps locus, 
which characterizes at lease 93 serotypes [8,9]. Various PCR-based 
molecular methods have been developed to detect serotype specific 
nucleotide sequences within the cps locus of S. pneumoniae 
(http://www.cdc.gov/ncidod/biotech/strep/pcr.htm). Recently, the Center for 
Disease Control and Prevention in the USA has developed a seven-triplexed 
real-time PCR system for identification of serotypes of 13-valent conjugate 
vaccine (PCV13) [10]. This system is probe-based system, which is more 
expensive than dye based system and lacked the description of quantitative 
detection of serotypes. 
 
To meet the need of epidemiological studies at affordable price, we have 
developed nanofluidic real-time PCR system for identification and 
quantification of serotypes. In this system, we have used 29 primers pairs, 
which can identify and quantify 50 serotypes (in 29 groups), including all 
vaccines serotypes of not only conjugate vaccines but also polysaccharide 
vaccine (PPV23). Primers were collected from Centers for Disease Control 
(CDC) and previous publication [11], and 14 new primers were designed so 
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that all primers amplified the target in same temperature and condition. All the 
primers were tested for sensitivity, specificity, repeatability, accuracy and 
reproducibility according to Minimum Information for Publication of 
Quantitative Real-time PCR Experiments (MIQE) guidelines [12]. The assay 
was validated with conventional culture and serotyping by applying in 
nasopharyngeal samples from the children with pneumonia confirmed by 
chest X-ray. The assay was sensitive to detect with the minimum detection 
level of 30-300 copies of DNA, specific to the target and can test 45 samples 
at a run (high-throughput).  
 
After developing and validating the assay, we have applied it to the 
nasopharyngeal samples of acute respiratory infections (ARI) cases and 
healthy children in Vietnam.  We have found 2 major findings: a positive 
correlation of serotype/serogroup bacterial load with prevalence of 
serotypes/serogroups and association of multiple serotype co-colonization 
with acute respiratory infections (ARI) in children. To our knowledge, both of 
these findings are novel in the epidemiology of pneumococcal serotypes.  
 
In conclusion, we have developed and validated a highly sensitive, specific 
and quantitative real-time PCR assay based on nanofluidic platform. With the 
help of the assay, we could decipher the relationship between the serotype 
specific bacterial load with its prevalence and the association of multiple 





Figure 1. The nanofluidic real-time PCR system for identification and 
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Serotype-specific quantification data are essential for elucidating the complex 
epidemiology of Streptococcus pneumoniae and evaluating pneumococcal 
vaccine efficacy. Various PCR-based assays have been developed to 
circumvent the drawback of labour-intensive and time-consuming culture-
based procedures for serotype determination and quantification of 
pneumococcus. Here, we applied a nanofluidic real-time PCR system to 
establish a novel assay. Twenty-nine primer pairs, 13 of which were newly 
designed, were selected for the assay to cover 50 serotypes including all 
currently available conjugate and polysaccharide vaccine serotypes. All primer 
pairs were evaluated for their sensitivity, specificity, efficiency, repeatability, 
accuracy and reproducibility on the Fluidigm Biomark HD System, a 
nanofluidic real-time PCR system, by drawing standard curves with a serial 
dilution of purified DNA. We applied the assay to 52 nasopharyngeal swab 
samples from patients with pneumonia confirmed by chest X-ray to validate its 
accuracy. Minimum detection levels of this novel assay using the nanofluidic 
real-time PCR system were comparable to the conventional PCR-based 
assays (between 30 and 300 copies per reaction). They were specific to their 
targets with good repeatability (SD of copy number of 0.1), accuracy (within 
±0.1 fold difference in log10 copy number), and reproducibility (SD of copy 
number of 0.1). When artificially mixed DNA samples consisting of multiple 
serotypes in various ratios were tested, all the serotypes were detected 
proportionally, including a minor serotype of one in 1000 copies. In the 
nasopharyngeal samples, the PCR system detected all the culture positive 
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samples and 22 out of 23 serotypes identified by the conventional method 
were matched with PCR results. We conclude that this novel assay, which is 
able to differentially quantify 29 pneumococcus groups for 45 test samples in 
a single run, is applicable to the large-scale epidemiological study of 
pneumococcus. We believe that this assay will facilitate our understanding of 
the roles of serotype-specific bacterial loads and implications of multiple 






















Streptococcus pneumoniae is a leading cause of death in children aged less 
than 5 years worldwide. It was responsible for ~6% of total deaths among the 
world population in 2008 [1]. It is a Gram-positive bacterium with a 
polysaccharide capsule, which enables the bacteria to evade the host defense 
mechanism. The antigenic structure of the capsule polysaccharide chain is 
determined by a series of glycosyltransferases encoded by the cps locus and 
characterizes at least 93 serotypes. The serotype distribution associated with 
invasive pneumococcal diseases varies according to the geographical 
regions, as does the efficacy of pneumococcal conjugate vaccines (PCV) [2]. 
After the introduction of the heptavalent conjugate vaccine (PCV7), an 
increase in the frequency of nonvaccine serotypes was observed and this has 
become a major global health concern [3,4]. In addition, different serotypes 
have caused death in a different age group [5], and some serotypes were 
associated with fatal illness both in the young and the elderly [6]. Hence, to 
understand this complex epidemiology of pneumococcal diseases requires 
large-scale surveillance in a serotype specific manner. 
 
Various PCR-based molecular methods have been developed to detect 
serotype-specific nucleotide sequences within the cps locus of S. pneumoniae 
(http://www.cdc.gov/ncidod/biotech/strep/pcr.htm). It was revealed that a 
considerable proportion of individuals were colonized by more than one 
serotype [7] and in some cases of invasive pneumococcal diseases, multiple 
serotypes have been isolated [8,9]. Furthermore, accumulating data have 
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shown that quantification of S. pneumoniae was also important, as the 
bacterial load was associated with disease severity [10,11]. Therefore, we 
believe that it is essential to undertake surveillance of multiple serotypes in 
pneumococci colonization and infection, and measure serotype-specific 
bacterial loads both in clinical and a large-scale epidemiology studies. 
However, there had been no assay that could accurately quantify S. 
pneumoniae at the serotype level and detect a minor population of a 
subdominant serotype (present in multiple serotypes) circulating in the field. 
To address these issues, we applied a nanofluidic real-time PCR system and 
established a novel assay. This assay could identify and quantify 29 
serotypes/serogroups (17 individual serotypes and 33 serotypes in 12 groups; 
in total 50 serotypes), including all vaccine serotypes. In a single run, 45 
different clinical specimens could be tested with 29 serotype/serogroup-
specific and one autolysin (lytA) primer pairs, equivalent to 1350 individual 
PCRs in total; this has made it a high-throughput assay. Following the MIQE 
(Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments) guidelines [12], here we report the linear dynamic range, 
minimum level of detection (analytic sensitivity), correlation coefficient (r2), 
efficiency, analytic specificity, repeatability (intra-assay variance), accuracy 
and reproducibility (inter-assay variance) of this novel assay. We also applied 
the assay to 52 nasopharyngeal swab samples from patients with pneumonia 
confirmed by chest X-ray to validate the accuracy of the assay by comparing 
the results of the assay with the results of conventional serotyping (Table S1, 





Bacterial isolates for positive controls 
Twenty one clinical isolates of S. pneumoniae serotypes 1, 3, 4, 6B, 7F, 9V, 
10F, 10A, 11A, 14, 15B, 18C, 19F, 19A, 22F, 23F, 23A, 33F, 34, 35F and 35B 
were used; these were isolated from Japanese patients with invasive 
pneumococcal diseases such as pneumonia, meningitis, septicemia and otitis 
media as well as from healthy carriers. Seven additional isolates of serotypes 
2, 5, 8, 9N, 12F, 17F, and 20 (ATCC®6302, ATCC®6305, ATCC®6308, 
ATCC®6309, ATCC®6312, ATCC®6317 and ATCC®6320 respectively) were 
purchased from American Type Culture Collection. Bacteria were cultured on 
trypticase soy agar with 5% sheep blood in 5% CO2 atmosphere at 37°C 
overnight. All the isolates were confirmed as S. pneumoniae by optochin 
sensitivity test and bile solubility test according to the standard procedures 
(http://www.evaluations-standards.org.uk/), and the serotype was verified by 
latex agglutination test and Quellung reaction by pool antisera, and type and 
factor antisera, respectively, from Statens Serum Institut.  
 
DNA extraction and copy number determination 
DNA was extracted from the pneumococcal isolates by QIAmp DNA mini kit 
(Qiagen) following the manufacture’s protocol. DNA concentration was 
determined by NanoDrop spectrophotometer (Thermo scientific). The mean 
molecular mass of the genome DNA of S. pneumoniae was calculated from 
the whole genome nucleotide sequence data of 9 serotypes in the Genbank 
(serotypes 2, 3, 4, 6B, 11A, 14, 19A, 19F and 23F; GenBank accession 
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numbers CP000410.1, FQ312027.1, AE005672.3, CP002176.1, CP002121.1, 
CP001033.1, CP000936.1, CP001015.1 and FM211187.1) and was used to 
obtain copy number values in the standard DNA samples. 
 
Primer design and the conventional real-time PCR condition 
Thirteen primer pairs targeted for serotype-specific sequence in the cps locus 
[13,14] were newly designed by Primer 3 software (http://frodo.wi.mit.edu/) 
and their specificity was checked by Primer BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Remaining primers, which 
amplified their respective targets at the same condition of PCR, were adopted 
from the previous publication and were also checked for their specificity in our 
sample set. All the primers sequences were checked again in silico for their 
representative targets by BLASTN (http://www.ncbi.nlm.nih.gov/Blast), where 
each primer showed 100% identity exclusively to its specific target sequence 
with significant E-values. Sequences and target sites of the primers are listed 
in Table 1. All the 30 primer pairs were tested for their sensitivity and 
specificity first in LightCycler 480 real-time PCR system (Roche) with a 384-
well heat block, at the final concentration of 0.4 µΜ of each. Real-time PCR 
was set up with 2x concentrate of SsoFast EvaGreen Supermix with Low 
ROX (BioRad) in which EvaGreen® (Biotium) was used as a detecting dye; a 
10 µl reaction consisted of 5.0 µl of SsoFast EvaGreen Supermix with Low 
ROX, 0.4 µl of each 10 µM primer solution, 2 µl of DNA sample and 2.2 µl of 
deionized water. The thermal cycle conditions were: initial incubation for 
enzyme activation at 98°C for 3 min (ramp rate 4.8°C/s), 45 × two-step cycle 
[denaturation at 98°C for 30 s (ramp rate 4.8°C/s) and annealing/extension at 
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59°C for 30 s (ramp rate 2.5°C/s)]. Fluorescence signals were acquired at the 
end of each annealing/extension stage (59°C). After the completion of the 
PCR, a melting curve analysis for the test of specific products of the PCR was 
performed from 65°C to 98°C continuously at the ramp rate of 0.11°C/s. The 
minimum level of detection was determined as the lowest copy number of 
DNA in the triplets when all the three reactions were positive, this was done 
by 10-fold serial dilutions of the DNA samples from 3 × 106 to 3 copies per 
reaction with each reaction in triplets and standard curves were drawn for 
each serotype-specific primer from the Cq values of the DNA samples. The 
minimum level of detection, efficiency and correlation coefficient (r2) of each 
primer pairs were determined in the LightCycler 480 real-time PCR system 
(Supplementary Table 1).  The autolysin (lytA) primers were used for the 
identification of S. pneumoniae and for quantification of total pneumococcus 
load (Table 1). The specificity of the lytA primers was verified by testing with 
all the available standard samples of S. pneumoniae and other bacterial 
species, Streptococcus mitis, Neisseria meningitidis, Haemophilus influenzae 
b and Moraxella catarrhalis. All the primer pairs that first worked out on the 
conventional real-time PCR system were adopted into the nanofluidic real-
time PCR system. 
 
Specific target amplification and the nanofluidic real-time PCR system 
Following the manufacturer’s recommendation, specific target amplification 
(STA) was performed in Applied Biosystems Veriti 96-well thermal cycler (Life 
Technologies) as the initial step for BioMark HD system (Fluidigm). In brief, 
STA pooled primer mix was prepared by mixing the forward and reverse 
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primers for the same 30 amplicons as above, and diluted with 10 mM Tris HCl 
and 0.1 mM EDTA (pH 8) so as to make the concentration of 200 nM of each 
primer. Then, 8.0 µl STA reaction was prepared by adding 4.0 µl TaqMan 
PreAmp Master Mix (Applied Biosystem), 2.0 µl STA pooled primer mix and 
2.0 µl DNA solution. The final concentration of each primer in the STA reaction 
was 50 nM. STA was performed with activation at 98°C for 10 min, and 14 × 
two-step cycles (denaturation at 98°C for 15 s and annealing/extension at 
59°C for 4 min). The STA product was diluted five times with 10 mM Tris/HCl 
and 0.1 mM EDTA (pH 8) before proceeding to the next step. 
 
Sample premix and assay premix were prepared in the wells of 96-well plates 
according to the manufacturer’s protocol (http://www.fluidigm.com/product-
documents.html), and 5 µl of each was transferred to the inlet of the primed 
48.48 Dynamic Array IFC chip (Fluidigm). The chip was set to the IFC 
Controller MX (Fluidigm). The 6.25 nl reaction chambers were filled up with 
PCRs containing 4.5 µM of each of specific primers and 40-fold diluted STA 
products containing negligible concentrations of carried-over STA primers 
(1.25 nM each) in 1 x SsoFast EvaGreen Supermix with Low ROX. 
Nanofluidic real-time PCR was carried out on the Fluidigm Biomark HD 
System with the thermal cycle conditions of: initial incubation for enzyme 
activation at 98°C for 3 min (ramp rate 2°C/s) and 40 x two-step cycles 
[denaturation at 98°C for 30 s (ramp rate 2°C/s) and annealing/extension at 
59°C for 30 s (ramp rate 2°C/s)]. Fluorescence signals were acquired at the 
end of each annealing/extension stage (59°C). After the completion of the 
PCR, a melting curve analysis for the test of specific products was performed 
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from 65°C to 98°C continuously at the ramp rate of 0.11°C/s. Quantitative 
analysis was carried out by using the crossing point (Cq) values of the PCRs 
with proper melting curves [15]. 
 
Standard curve and quantification in the nanofluidic real-time PCR 
system 
Standard curves for real-time PCR were drawn with three independent serial 
10-fold dilutions from 3 x 106 copies to 3 copies per 2 µl (the volume used in a 
single assay), which were made in the background of λ phage DNA (Takara 
Bio) at a constant concentration of 1 ng/µl. The linear standard curves were 
constructed by using real-time PCR Analysis software implemented in the 
detection system. For the quantification of test samples, two positive controls 
(mixture of multiple different isolates at known concentrations) and one 
negative control (λ DNA alone) were included in each run. The serotype-
specific copy number of unknown samples was determined by analyzing the 
value of Cq in the equation of the standard curve of the serotype. 
 
Determination of linear dynamic range, correlation coefficient (r2), 
efficiency, analytical sensitivity, analytical specificity, repeatability, 
accuracy and reproducibility in the nonofluidic real-time PCR system 
Linear dynamic range was tested from 3 copies to 3 x 106 copies in the 
standard curves.  The coefficient of correlation (r2) of each standard curve 
was determined. Amplification efficiency (e) of a given primer pair was 
calculated by e = 10-1/m -1, where m was the slope of the standard curve. 
Analytical sensitivity (lower limit of detection) was determined as the minimum 
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number of copies of DNA that could be measured by the primers in the ten-
fold serial dilutions of the purified DNA sample. Analytical specificity of each 
primer pair was assessed by cross-checking each with 28 available 
pneumococcal isolates as well as four non-pneumococcal bacteria in a single 
run of nanofluidic real-time PCR system and melting curve analysis of their 
amplification products. Intra-assay variation (repeatability) was assessed by 
replicating the same samples for four times for vaccine serotypes and two 
times for non-vaccine serotypes in the same assay run, and presented as SD 
for copy number of the samples. Accuracy of each primer pair was calculated 
as the ratio of difference between the observed copy number (in log10) and the 
expected copy number (in log10) to the expected copy number (in log10). Inter-
assay variation (reproducibility) was computed as the SD of copy number (in 
log base 10) in different runs of the assay.  
 
Artificial DNA mixture of multiple serotypes for assessment of detection 
and quantification of minor serotypes in the nanofluidic real-time PCR 
system 
To confirm the effectiveness of quantitative detection of multiple serotypes in a 
single specimen by the nanofluidic real-time PCR system, we prepared mixed 
DNA samples of two different serotypes to imitate those of multi-serotype    
co-colonization with different contributions of minor population at 1:10, 1:100 
and 1:1000 ratios. 
 
Application of the assay to clinical specimens 
In total, 52 nasopharyngeal swab samples from children with pneumonia 
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confirmed by chest X-ray and collected in a government referral hospital in 
central Vietnam were examined for the presence of pneumococcus and 
serotype determination by conventional microbiological/serological methods, 
as described previously [16]. DNA were extracted from these nasopharyngeal 
swab samples and used to verify the practical usefulness of the nanofluidic 























Linear dynamic range, correlation, sensitivity, specificity and efficiency 
of the assays in the nanofluidic real-time PCR system 
The amplification signals remained specific to the target at least until cycle 25 
in the nanofluidic real-time PCR system, as confirmed by melting curve 
analysis. The linear dynamic range was four to five orders of magnitude for all 
the primer pairs. Within these dynamic ranges, the correlation coefficients (r2) 
of the assays were 0.99 except for the assay of serotype 3, which was 0.98. 
The minimum levels of detection of all primer pairs were between 30 and 300 
copies of the genome per 2 µl DNA sample (Table 2). All the primer pairs were 
specific to their own targets as shown in Table 3. Fig 1 illustrates the heat map 
output of the validation assay. Efficiency of the primers ranged from 80 to 
110%, except for the assays for serotypes 22F/22A and 33F/33A/37 that had 
71 and 72% respectively (Table 2). Collectively, all the assay designs were 
successful in amplifying the intended targets with a high sensitivity, specificity 
and linearity on the nanofluidic real-time PCR system.  
 
Repeatability, accuracy and reproducibility of the assays in the 
nanofluidic real-time PCR system 
With regard to repeatability (intra-assay variation), the SD of the copy number 
(in log10) in the tests for replicated standard DNA in the same run was 
calculated for each primer pair at the target concentrations of 3 x 105 copies 
per reaction.  It was <0.10 for all primer pairs (Table 2). With regard to 
accuracy, at a target concentration of 3 x 105 copies per reaction, the fold 
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difference in copy number (in log10) from the observed values was within +/- 
0.10 for all primers pairs except for serotype 35B, which had + 0.12 (Table 2). 
With regard to reproducibility (inter-assay variation), the SD of the copy 
number (in log10) at the target concentrations of 3 x 105 copies per reaction 
between different runs was <0.10 for all primers except for serotype 
33F/33A/37 and 12F/12A/12B/44/46, which had 0.111 and 0.105 respectively 
(Table 2).  Collectively, with a few exceptions, the indices for assay 
parameters fell within the range of excellent performance: repeatability of 
0.10, accuracy of between - 0.10 to +0.10 and reproducibility of 0.10. 
 
Multiple serotype detection in a single specimen 
As a representative result of several trials, the recovery (the efficiency of 
quantitative detection of the minor populations in the presence of excessive 
amount of non-target DNA) of minor population at the ratios of 1:10, 1:100 
and 1:1000 were within log10 of +/-0.5; 0.38 (log10 of -0.42), 1.20 (log10 of 
0.08) and 0.62 (log10 of -0.20) for the respective ratios (Table 4). Using similar 
experiments with artificially mixed DNA consisted of multiple serotypes in 
various ratios repeated several times, we could demonstrate that all the 
serotypes in the samples were detected almost proportionally, even if the 
minor components were as few as one in 1000 copies. 
 
Comparison of the nanofluidic real-time PCR system with conventional 
culture and serotyping methods in the clinical samples 
Fifty-two nasopharyngeal swab samples from the confirmed pneumonia cases 
that had been examined by conventional culture and serotyping methods 
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were tested by the nanofluidic real-time PCR system to demonstrate practical 
utility of the method. The PCR-positive rate was higher than culture-positive 
rate; 40 out of 52 were PCR-positive and all 23 culture-positive samples were 
PCR-positive also (Table 5). Serotyping results of the nanofluidic PCR system 
for 23 culture-positive samples well matched with those of conventional 






Bacterial culture and serological typing remain the gold standard methods for 
pneumococcal serotype identification, but they are expensive, labor-intensive 
and less sensitive especially if antibiotics were administrated prior to the 
sample collection. Various PCR and antibody based molecular methods have 
been developed to overcome the drawbacks of the conventional 
bacteriological and serological procedures for serotype identification and 
quantitative detection of S. pneumoniae. These molecular techniques include 
oligonucleotide probe array [17-19], immunoblot [20] and immunoassay [21]. 
Multiplex PCR and real-time PCR have increased substantially the sensitivity 
of diagnosing pneumococcal diseases even in culture-negative cases [22] and 
identifying the presence of pneumococcus in the nasopharyngeal colonization 
[23,24]. Most multiplex PCR serotyping procedures use different sets of 
primers targeting for several serotypes/serogroups, and have been used in 
epidemiological studies [25-29], mainly because of their cost effectiveness. 
Real-time PCR is more sensitive than multiplex PCR [30], and has been used 
as clinical diagnostics too [31,32]. Real-time PCR assays have a considerable 
advantage to multiplex PCR assays because they provide quantitative data. 
Obtaining quantitative data has been realized important, as the 
nasopharyngeal bacterial load of pneumococcus is associated with severity of 
pneumonia and fatal outcome, both in children and adults [10,11,16]; this was 
also applied to the prediction of pneumonia [33]. Our novel assay, which is 
based on the nanofludic real-time PCR system, has all characteristics of a 
rigorous real-time PCR assay, such as high sensitivity, specificity, accuracy, 
efficiency, repeatability and reproducibility, and also provides high-throughput 
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qualitative and quantitative data, even of minor populations of subdominant 
serotypes.  
 
For the identification of S. pneumoniae, several genes are used as the target 
genes for quantitative PCR assays, such as autolysin (lytA), pneumolysin 
(ply), pneumococcal surface adhesin A (psaA) and a gene for hypothetical 
protein Spn9802 [34]. Among them, lytA has proved to be one of the most 
sensitive and specific targets, and is capable to differentiate S. pneumoniae 
from S. pseudopneumoniae [31,35-37].  Therefore, we adopted lytA primers 
for the confirmation of S. pneumoniae in this assay. We think lytA primers 
should be included when testing clinical samples along with the serotype 
specific primers, as it will estimate the total bacterial load of S. pneumoniae, 
including serotypes not covered by the assay. Although several studies of 
real-time PCR for quantification of pneumococcal bacterial load have been 
published, most lacked the detail description on the assay performance 
[10,30,38,39]. Regarding total bacterial load estimation, our quantitative assay 
has a comparable performance to the previously published assays in terms of 
sensitivity, specificity and reproducibility; there are only a few exceptional 
reports that describe assay performance in detail, having ~10 copies of the 
lower limit of detection, five orders of linear dynamic range and 0.3-1 cycles of 
reproducibility [40,41]. For serotype-specific assays, there have been no 
previous reports about the assay performance for comparison; we could 




Co-colonization of multiple serotypes of S. pneumoniae is another emerging 
epidemiological concern because it may have an influence on the efficacy of 
pneumococcal vaccine [4,42].  In this nanofluidic real-time PCR system, the 
presence of minor serotype (in multiple serotype) could be identified precisely 
even down to as few as one in 1000 copies of background pneumococcal 
DNA, as demonstrated by mixed DNA samples in Table 4. This ability to 
detect multiple serotypes, even in a lower population density of pneumococci, 
is one of the novelties of the assay. This assay has a wide coverage of 50 
prevalent serotypes in the field, including all currently available vaccine 
serotypes, and has a considerably high throughput. Quantitative data of 30 
amplicons for 45 test samples, equal to 1,350 PCRs, can be obtained by a 
single run in ~4 h including a STA step prior to the nanofluidic real-time PCR 
system.  Furthermore, only 1/30 of PCR reagents are required in this assay 
compared to conventional real-time PCR, which results in a lower running 
cost and makes our assay cost-effective. Considering all these characteristics 
of this novel assay, we think it has met the demand for an efficient and cost-
effective quantitative assay for large epidemiological studies of S. 
pneumoniae. 
 
Recently, the Centers for Disease Control and Prevention in the USA has 
developed a seven-triplexed real-time PCR system for identification of 
serotypes of PCV13 [43]. This system can identify 11 individual serotypes and 
10 serogroups in 7 triplexed reactions using probe based chemistry. In our 
nanofluidic real-time PCR system, we can identify 17 individual serotypes and 
12 serogroups (33 serotypes) including all vaccine serotypes of PCV13 and 
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PPV23. We used EvaGreen, a dsDNA-binding dye, which is cheaper than the 
probe based chemistries, and obtained sensitivity and specificity comparable 
to the probe-based system used by the Centers for Disease Control and 
Prevention. 
 
One of the limitations is the initial cost of purchasing the nanofluidic 
equipment. The current price is about five to 10 times higher than a 
conventional real-time PCR machine. Another limitation, which is common to 
all PCR-based methods, is that some serotypes could not be identified 
individually by single primer sets. We could not use primer specific for 
serotypes 6C/6D; instead, we used primers for serotypes 6A/6B and 
serotypes 6A/6B/6C/6D in our assay (Table 3). A similar overlap of specificity 
exists between assay 28 specific to serotype 34, and assay 29 specific to 
serotypes 34/35F. All the serotyping assays are practically free of false-
positive reactions because of cross-reaction between different serotypes and 
free of false negative reactions because of competition between primers, 
which may take place in conventional multiplex PCR assays.  
  
In conclusion, we have developed a reliable assay based on the nanofluidic 
real-time PCR system for molecular serotyping of pneumococcus, which can 
provide qualitative and quantitative data of 50 pneumococcal serotypes in 29 
groups directly from 45 test samples in a single run. As it can quantify 
pneumococcal load at the serotype/serogroup level, we expect it may help us 
to understand the role of serotype-specific pneumococcal loads in the 
pathogenesis of the pneumococcal diseases, particularly when multiple 
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serotypes are present. To the best of our knowledge, this is the first report of 
serotype/serogroup-specific quantitative real-time PCR assay of 
pneumococcus with detailed performance data presented according to the 
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Table 1. Primers for nanofluidic real-time PCR serotyping. 
 
Assay Specificity Target gene 
GenBank 




Identification of S. pneumoniae 
1 lytA lytA AE005672 TCGTGCGTTTTAATTCCAGC TGACGGACTACCGCCTTTAT 106 bp New 
Serotype determination 
2 1 wzy Z83335  GGGACTTTAATTTTATGCAGTG CACAATGGCTTTAGAAGGTAGAG 270 bp Kong (17) 
3 2 wzy CR931633 TATCCCAGTTCAATATTTCTCCACTACACC ACACAAAATATAGGCAGAGAGAGACTACT 290 bp CDC 
4 3 galU CR931634 GTGAATTTGTGGGCAAACG ATTGCTTACCAAGTGCAATAACG 132 bp New 
5 4 wzy CR931635 GCGGGTAGGATTTTAACAGG TCCTGAACTAGCTGCCTCTG 120 bp New 
6 5 wzy CR931637 CAACTTCTGATTATGCCTTTGTG CAAAGCAATAGTGCTAATTAAACAAC 126 bp New 
7 6A/6B/6C/6D wzy AF316640  TCAACCTGCAGTAATTTTAACA CTACTTTCTGAATTTCACGGATATAAAG 293 bp Kong (17) 
8 6A/6B wciN HQ662200 TCTGGGAAGTGTTCTTCCATC CACCCCATAGAGAATTTTACCC 124 bp New 
9 7F/7A wzy CR931643 CAAACTATTACAGTGGGAATTACGG GGACCATACAATAAGCGCAAT 130 bp New 
10 8 wzy CR931644  GAAGAAACGAAACTGTCAGAGCATTTACAT CTATAGATACTAGTAGAGCTGTTCTAGTCT 201 bp CDC 
11 9V/9A wzy CR931648 GGTTCAAAGTCAGACAGTGAATCT AAAAGAGGCTTTCAATTGTTGTT 122 bp New 
12 9N/9L wzy CR931647  TCAATGGCGACTTTATTTGC AGTCTATTATCTCCTGTAGGGTGC 362 bp Kong (17) 
13 10A wcrG CR931649 AGACGACAAGATTGCGACAG AAGGTGATCCGCTACCACAT 121 bp New 
14 10F/10C/33C wzx CR931652 GATCTATGATCAGGCACTTAAGTTG TTAACCGCTTTGTGTTCACC 120 bp New 
15 11A/11D/11E/11F wzx CR931653 GTTCAGGTGATTTCCCAATATAGTG TCGTTAAAATCAACAGCAACTG 109 bp New 
16 12F/12A/12B/44/46 wzy CR931660 TGAATATGGACGGTGGAG AGCAAAGAAAGCCGAAAG 242 bp Kong (17) 
17 14 wzy X85787  CCTACTTCCAAAACAGTTTATGC GTCCATAGCACCATACAAAAAGAC 129 bp Kong (17) 
18 15B/15C wzy CR931664  TAATAAGCGGATGATTGTAGCG TATACTGATTAACTTTCCAGATGGG 352 bp Kong (17) 
19 17 wzy CR931670  AGAGGGATTGTTGAAGGTATTC AGTAGTCTCGCATTTCTATCATCC 308 bp Kong (17) 
20 18F/18A/18B/18C wzy AF316642  AATTGTTCTTTTCCTGTACTCAGTC CGAACCATTGAAACTATCATCTG 271 bp Kong (17) 
21 19F wzy U09239  TCAGTATTTGCACTGGTTAATTC AAGAACAAGGTTGTATATTTCCTTC 249 bp Kong (17) 
22 19A wzy AF094575  TGTATTTGCCCTTATTAATGTGC AAGTGCAAGATTATGAATCTCTCTC 247 bp Kong (17) 
23 20 wzy CR931679  CTTTATCAGGAATACGCCAATC CTGTATAATAACGAGAACCAACG 300 bp Kong (17) 
24 22F/22A wzy CR931682  AGGATGCAGTAGATACCAGTGG TATAAACGGAGGTTGTTGTCC 354 bp Kong (17) 
25 23F wzy AF057294  TGATAGTGAACTTGGGATTGTC CTTTATCGGTAAGGTGGATAAG 245 bp Kong (17) 
26 23A wzy CR931683 CTGGGAATTGGCACTCTTCT GCCGCAAAGAGATACGAAC 103 bp New 
27 33F/33A/37 wzy CR931702  GAAGGCAATCAATGTGATTGTGTCGCG CTTCAAAATGAAGATTATAGTACCCTTCTAC 338 bp CDC 
28 34 wzy CR931703 TGACTGGTAGTAGAGGGTCCTTG GAGGAGCAACTGCCACTACA 147 bp New 
29 35F/34 wcrO CR931707 TATTAGTATTTGTGAAGAAAATAACCTGACC TATCAATATCGTCATCCCAAGG 107 bp New 
30 35B wcrH CR931705 TACGCTTTCCCAAGTTTCCT CTCCGTACATTGGATGTTGG 144 bp New 
†New: newly designed in this study; CDC, Centers for Disease Control and Prevention. (http://www.cdc.gov/ncidod/biotech/files/pcr-oligonucleotide-primers.pdf) 
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Table 2. Performance of the nanofluidic real-time PCR serotyping. 
 
Assay Specificity r2 Efficiency Limit of detection Intra-assay variation Accuracy Inter-assay variation 
   (%) (Copies) (SD of Copy number) (Fold changes of Copy 
number) 
(SD of Copy number) 
1 lytA 0.99 94 30 0.009 0.039 0.023 
2 1 0.99 108 30 0.016 -0.079 0.068 
3 2 0.98 100 30 0.015 -0.066 0.058 
4 3 0.99 90 300 0.040 -0.055 0.002 
5 4 0.99 99 300 0.015 -0.052 0.017 
6 5 0.99 90 300 0.024 -0.050 0.041 
7 6A/6B/6C/6D 0.99 92 300 0.011 -0.016 0.088 
8 6A/6B 0.99 93 300 0.010 -0.081 0.084 
9 7F/7A 0.99 84 300 0.014 -0.051 0.036 
10 8 0.99 94 300 0.002 -0.062 0.054 
11 9V/9A 0.99 102 30 0.002 0.000 0.050 
12 9N/9L 0.99 123 300 0.010 0.004 0.027 
13 10A 0.99 101 300 0.038 -0.057 0.013 
14 10F/10C/33C 0.99 94 300 0.013 -0.055 0.040 
15 11A/11D/11E/11F 0.99 99 30 0.015 -0.083 0.087 
16 12F/12A/12B/44/46 0.99 103 300 0.028 -0.004 0.105 
17 14 0.99 108 300 0.046 -0.049 0.024 
18 15B/15C 0.99 95 30 0.020 -0.082 0.082 
19 17 0.99 94 30 0.014 -0.081 0.083 
20 18F/18A/18B/18C 0.99 85 30 0.016 -0.069 0.037 
21 19F 0.99 100 300 0.021 -0.088 0.088 
22 19A 0.99 80 300 0.012 -0.061 0.034 
23 20 0.99 80 300 0.013 -0.073 0.065 
24 22F/22A 0.99 71 300 0.008 0.076 0.046 
25 23F 0.99 93 300 0.018 -0.074 0.073 
26 23A 0.99 86 300 0.022 -0.051 0.038 
27 33F/33A/37 0.99 72 300 0.017 -0.079 0.111 
28 34 0.99 92 30 0.020 -0.050 0.024 
29 35F/34 0.99 108 300 0.011 -0.075 0.057 
30 35B 0.99 88 300 0.004 0.127 0.060 
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Table 3. Reaction patterns of nanofluidic real-time PCR serotyping of 28 
Streptococcus pneumoniae isolates 
 

































































































serotype 1 + + - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
serotype 2 
(ATCC®6302) + - + - - - - - - - - - - - - - - - - - - - - - - - - - - - 
serotype 3 + - - + - - - - - - - - - - - - - - - - - - - - - - - - - - 
serotype 4 + - - - + - - - - - - - - - - - - - - - - - - - - - - - - - 
serotype 5 
(ATCC®6305) + - - - - + - - - - - - - - - - - - - - - - - - - - - - - - 
serotype 6B + - - - - - + + - - - - - - - - - - - - - - - - - - - - - - 
serotype 7F + - - - - - - - + - - - - - - - - - - - - - - - - - - - - - 
serotype 8 
(ATCC®6308) + - - - - - - - - + - - - - - - - - - - - - - - - - - - - - 
serotype 9V + - - - - - - - - - + - - - - - - - - - - - - - - - - - - - 
serotype 9N 
(ATCC®6309) + - - - - - - - - - - + - - - - - - - - - - - - - - - - - - 
serotype 10F + - - - - - - - - - - - - + - - - - - - - - - - - - - - - - 
serotype 10A + - - - - - - - - - - - + - - - - - - - - - - - - - - - - - 
serotype 11A + - - - - - - - - - - - - - + - - - - - - - - - - - - - - - 
serotype 12F 
(ATCC®6312) + - - - - - - - - - - - - - - + - - - - - - - - - - - - - - 
serotype 14 + - - - - - - - - - - - - - - - + - - - - - - - - - - - - - 
serotype 15B + - - - - - - - - - - - - - - - - + - - - - - - - - - - - - 
serotype 17F 
(ATCC®6317) 
+ - - - - - - - - - - - - - - - - - + - - - - - - - - - - - 
serotype 18C + - - - - - - - - - - - - - - - - - - + - - - - - - - - - - 
serotype 19F + - - - - - - - - - - - - - - - - - - - + - - - - - - - - - 
serotype 19A + - - - - - - - - - - - - - - - - - - - - + - - - - - - - - 
serotype 20 
(ATCC®6320) + - - - - - - - - - - - - - - - - - - - - - + - - - - - - - 
serotype 22F + - - - - - - - - - - - - - - - - - - - - - - + - - - - - - 
serotype 23F + - - - - - - - - - - - - - - - - - - - - - - - + - - - - - 
serotype 23A + - - - - - - - - - - - - - - - - - - - - - - - - + - - - - 
serotype 33F + - - - - - - - - - - - - - - - - - - - - - - - - - + - - - 
serotype 34 + - - - - - - - - - - - - - - - - - - - - - - - - - - + + - 
serotype 35F + - - - - - - - - - - - - - - - - - - - - - - - - - - - + - 
serotype 35B + - - - - - - - - - - - - - - - - - - - - - - - - - - - - + 
other bacterial species 
S. mitis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
H. influenzae b - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
N. meningitidis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
M. catarrhalis - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Streptococcus pneumoniae strains, except for seven of those obtained from American Type 




Table 4. Quantitative detection of mixed DNA samples mimicking those of 
mixed co-infection/co-colonization with multiple serotypes of S. pneumoniae 
 
Mixed DNA 
Sample Major serotype Minor serotype 
Observed 
ratio Recovery of minor serotype
† 
Serotype 4: Serotype 5 = 1: 10 
 8.89 x 104 (copies/2µl) 3.44 x 103 (copies/2µl) 1: 0.0382 0.38 (log10 of -0.42) 
Serotype 7F: Serotype 9V = 1: 100 
 9.58 x 104 (copies/2µl) 1.15 x 103 (copies/2µl) 1: 0.0120 1.20  (log10 of -0.08) 
Serotype 10F: Serotype 11A = 1: 1000 
 7.23 x 104 (copies/2µl) 45.0 (copies/2µl) 1: 6.22 x 10-4 0.62 (log10 of -0.20) 




Table 5. Comparison of the results of conventional serotyping and the 
nanofluidic real-time PCR system in nasopharyngeal samples 
 
Serotype by the 
nanofluidic PCR 
system 
Serotype by the conventional method Culture 
negative Total 6† 6A 6B/6D 11 14 15 19F 23 
Serotypes 6A/6B 1 3 1 - - - - - 3 8 
Serotypes 6C/6D - - 1 - - - - - - 1 
Serogroup 11 - - - 1 1* - - - - 2 
Serotype 14 - - - - 5 - - - 2 7 
Serotypes 
15B/15C 
- - - - - 1 - - 2 3 
Serogroup 18 - - - - - - - - 1 1 
Serotype 19F - - - - - - 3 - 7 10 
Serotype 23F - - - - - - - 6 1 7 
Non-typeable - - - - - - - - 1 1 
PCR negative - - - - - - - - 12 12 
Total   3 2 1 6 1 3 6 29 52 
†Serotypes 6A/6B/6C/6D; serotyping reactions with factor sera were not 
certain. 
*The result of PCR nanofluidic serotyping was confirmed by separate PCRs 






Figure 1. Cross validation of target specificity of the nanofluidic real-time PCR 
serotyping assay. Intensity of DNA amplification signals from the nanofluidic 
real-time PCR is shown as a heat map; the brighter rectangles of the 
checkerboard mean the stronger signals (the smaller Cq values). Each row 
corresponds to a single target specificity and each column corresponds to a 
single DNA specimen. DNA specimens were from Streptococcus pneumoniae 
isolates except for 3, 11, 16, 25 and 33; 1: serotype 1, 2: serotype 17F 
(ATCC®6317), 3: Streptococcus mitis, 4: serotype 18C, 5: serotype 2 
(ATCC®6302), 6: serotype 19F, 7: serotype 3, 8: serotype 19A, 9: serotype 4, 
10: serotype 20 (ATCC®6320), 11: Neisseria meningitidis, 12: serotype 5 
(ATCC®6305), 13: serotype 22F, 14: serotype 6B, 15: serotype 23F, 16: 
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Haemophilus influenzae b, 17: serotype 7F, 18: serotype 33F, 19: serotype 8 
(ATCC®6308), 20: serotype 10F, 21: serotype 9V, 22: serotype 23A, 23: 
serotype 9N (ATCC®6309), 24: serotype 34, 25: Moraxella catarrhalis, 26: 
serotype 10A, 27: serotype 35F, 28: serotype 11A, 29: serotype 35B, 30: 
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Background: Among pneumococcal serotypes, some serotypes are more 
prevalent in the nasopharynx than others; determining factors for higher 
prevalence remain to be fully explored. As non-vaccine serotypes have 
emerged after the introduction of 7-valent conjugate vaccines, study of 
serotype specific epidemiology is in need. When two or more serotypes co-
colonize, they evolve rapidly to defend host’s immune responses; however, a 
clear association of co-colonization with a clinical outcome is lacking.  
 
Methods: Children less than 5 years old who were admitted to hospital due to 
acute respiratory infections (ARI) (n=595) and healthy children (n=350) were 
recruited. Carriage of pneumococcus was determined by culture and lytA PCR 
in the nasopharyngeal samples. Serotype/serogroup detection and its 
quantification were done by the nanofluidic real-time PCR system. 
Spearman’s correlation and logistic regression were used to examine a 
correlation of serotype/serogroup specific bacterial load with its prevalence 
and an association of co-colonization with ARI respectively.  
 
Results: Serotype/serogroup specific bacterial load was correlated with its 
prevalence, both in ARI cases (Spearman’s rho = 0.44, n=186; P<0.0001) and 
healthy children (Spearman’s rho = 0.41, n=115; P<0.0001). The prevalence 
of multiple serotypes was more common in ARI cases than in healthy children 
(18.5 % vs 7.1 %; aOR 2.92, 95% CI: 1.27-6.71; P=0.01). The dominant 
serotype in the co-colonization had a 2 log10 higher bacterial load than the 




Conclusions: High bacterial load in the nasopharynx may help transmit 
pneumococci among hosts, and increase the chance of successful acquisition 
and colonization. Co-colonization of multiple serotypes of pneumococci is 
linked with ARI, which infers the interactions of multiple serotypes may 





















Streptococcus pneumoniae (pneumococcus) is a major cause of life 
threatening diseases including pneumonia, sepsis and meningitis in children 
worldwide [1]. Pneumococcus has distinct polysaccharide capsule which 
characterizes its more than 90 serotypes. It colonizes in the nasopharynx, 
which is the precursor for pneumococcal diseases and the source for 
transmission among people [2]. The emergence of non-vaccine serotypes 
(19A, 35B) after the introduction of 7-valent pneumococcal conjugate vaccine 
(PCV7) has become a concern for future epidemiology of pneumococcal 
diseases, and it highlights the need of serotype specific study of this common 
pathogen [3,4]. 
 
The prevalence of a serotype in the nasopharynx is inversely correlated with 
the invasiveness of the serotype [5]. Less invasive serotypes such as 6A, 6B, 
19F, 23F tend to colonize more frequently and maintain the carriage for longer 
time; while the more invasive serotypes such as 1, 4, 5, 7F tend to colonize 
less frequently and maintain colonization for less duration [6,7]. The 
pneumococcal capsule, which is a major virulent factor, determines the 
serotype. It is found the thickness of the capsule positively correlates with the 
prevalence of the serotype/serogroup [8]. Furthermore, the capacity to grow of 
a serotype is correlated with its prevalence in an in vitro study [9]; however, it 
is unknown whether similar relationship exists in the natural niche in humans.  
 
Co-colonization of multiple pneumococcal serotypes in the nasopharynx 
affects vaccine serotype replacement, carriage detection and pneumonia 
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diagnosis [10]. Accurate determination of co-colonization and its role in 
pathogenesis are difficult to establish by using conventional serotyping 
method because of its low sensitivity and tedious laboratory work; therefore, a 
highly sensitive and specific molecular method is in need to detect multiple 
serotypes accurately and efficiently [11,12]. Although varied prevalence rates 
of co-colonization have been reported from different parts of the world [11-15], 
an epidemiological evidence of their association with a clinical outcome is 
lacking. Some epidemiological models have demonstrated that the serotypes 
compete among themselves for acquisition and persistence of colonization in 
the nasopharynx [16,17]; however, it is yet to be demonstrated quantitatively 
in humans.  
 
In this study, we applied a highly sensitive and specific novel nanofluidic real-
time PCR system to identify serotypes/serogroups and quantify their bacterial 
load in nasopharyngeal samples of hospitalized acute respiratory infections 
(ARI) cases and healthy children.  We aimed to assess the correlation of 
bacterial load of specific serotypes/serogroups with the prevalence and 
compare the prevalence of co-colonization of multiple serotypes between 










Acute respiratory infections (ARI) cases, as defined by World Health 
Organization (WHO), were recruited in the Department of Pediatrics, Khanh 
Hoa General Hospital, Nha Trang City, Vietnam from 07/04/2008 to 
31/03/2009. The hospital has 750 beds, and is the only hospital that provides 
inpatient care for sick children in Nha Trang City. The participants were 
children under 5 years old from the study area, who were admitted to the 
pediatric ward during the study period with acute respiratory infections (ARI) 
defined by cough and/or difficulty in breathing (WHO). We also included 
healthy children to compare bacterial load and serotype distribution with ARI 
cases. Healthy children, who did not have fever, signs of respiratory infections 
or history of antibiotic intake in the month preceding the day of enrollment, 
were recruited from two communes in the study area. They were selected 
randomly during January 2008 from the under 5 years old children using the 
census data. Informed written consent was taken from the parents of the 
hospital admitted ARI cases and the healthy children. Details of the study site 
were described elsewhere [18]. 
 
Sample collection, storage and DNA extraction 
A nasopharyngeal sample (NPS), (about 100 microliter in volume) was 
collected flexible dacron-tipped aluminum-shafted swabs (Copan, Brescia, 
Italy) from each participant according to the WHO protocol [19]. The samples 
were taken from ARI cases at the time of admission before they were treated 
with antibiotics. The samples were divided into two aliquots. One aliquot was 
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sub-cultured onto 5% sheep blood agar and incubated overnight with 5% CO2 
at 37°C. Alpha hemolytic colonies with morphology suggestive of S. 
pneumoniae and positive Optochin test were considered potential S. 
pneumoniae isolates. The other aliquot was stored at -80°C. At a later stage 
DNA was extracted, following the protocol of QIAGEN kit for the Gram-
positive bacteria, directly from the nasopharyngeal samples of the children 
from whom potential S. pneumoniae had been cultured. DNA was stored at -
80°C, except for transportation to Nagasaki on dry ice, till used for the lytA 
PCR and the nanofluidic real-time PCR system. 
 
Identification of pneumococcus, its serotypes, quantification of bacterial 
load and definition of co-colonization of multiple serotypes 
The DNA extract of the NPS from children with a potential S. pneumoniae 
culture positive isolate was analyzed by a lytA PCR that targeted the autolysin 
gene using the Light cycler II (Roche). Carriage of pneumococcus is defined 
as having positive lytA PCR NPS. The lytA positive samples were subjected to 
the nanofluidic real-time PCR system for molecular serotyping. The 
nanofluidic real-time PCR system can identify 50 serotypes in 29 groups, and 
it can detect minor population of multiple serotypes in co-colonization of 
pneumococci with the minimum level of detection of 30 to 300 copies. Total 
and specific serotype/serogroup bacterial loads were quantified using the 
standard curves. Details of the nanofluidic real-time PCR system has been 
described elsewhere [20]. Samples positive for lytA and negative for all 
serotype/serogroup primer-pairs were grouped as non-typeable (NT). Co-
colonization with multiple serotypes was defined as the presence of two or 
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more serotypes/serogroups in a sample. In co-colonization the first serotype 
and second serotype were defined according to their bacterial loads; a 
serotype with the highest load was assigned as first serotype, with the second 
highest load as second serotype.  
 
Statistical analysis 
The data of pneumococcal loads, DNA copies, were changed into log10 scale. 
To compare the groups, Wilcoxon rank sum test was used for the continuous 
variables and Chi-square or Fisher exact test was used for categorical 
variables. Logistic regression was used to test the effects of pneumococcal 
load and co-colonization as risk factors for hospitalized children due to ARI. 
Odds ratios were adjusted for age, sex and daycare attendance. To test the 
correlation of bacterial load and prevalence of individual serotypes, 
Spearman’s correlation was used. Analyses were performed using Stata 
v12.1 (StataCorp, College Station, Taxes, USA). 
 
Ethical approval 
This study was approved by all the concerned research review boards: 
Nagasaki University Institutional Review Board Nagasaki, Japan; the National 
Institute of Hygiene and Epidemiology Scientific Review Committee, Hanoi 







Basic characteristics of ARI cases and healthy children 
Among the hospital admitted ARI cases, 88.6 % (527/595) were children less 
than 2 years old, proportion of male was 62% (369/595), and the median age 
was 10 months. Almost half, 45.5% of ARI cases had history of antibiotic use 
before admission. The proportion of chest X-ray confirmed pneumonia among 
them was 22.8% (136/595).  Among healthy children, 55.4% (194/350) were 
under 2 years of old, proportion of male was 52.6% (184/350), and the 
median age was 19 months.  
 
Pneumococcal colonization and serotype distribution  
Pneumococcal carriage rate was 32.6 % (194/595) in ARI cases and 40% 
(140/350) in healthy children (figure 1). The proportion of typeable serotypes 
in ARI cases and healthy children were 95.9% (186/194) and 82.1% (115/140) 
respectively. Thirteen serotypes/serogroups of pneumococcus were detected 
in ARI cases and healthy children (figure 2).  Serotypes/serogroups 19F, 
6A/6B, 23F and 6C/6D were more prevalent in hospitalized ARI cases while 
serotypes/serogroups 14, 6A/6B, 19F, 15B/15C, 11 and non-typeables (NT) 
were common in healthy children. The proportion of serotypes/serogroups 
covered by pneumococcal conjugate vaccines: 7-valent (PCV7), 10-valent 
(PCV10) and 13-valent (PCV13) were approximately equal to one another, 
which was about 74% in ARI cases and 55% in healthy children (this was an 




Pneumococcal bacterial load 
Higher bacterial load was associated with hospitalization due to ARI. The 
median bacterial load (total) was 6.61 log10/ml in ARI cases and 4.36 
log10/ml in healthy children (OR=9.96, 95%CI: 6.39-15.52; P<0.0001 and 
aOR=9.07, 95%CI: 5.69-14.4; P<0.0001). There was no difference in median 
bacterial load between males and females both in ARI cases (6.62 log10 in 
male Vs. 6.59 log10 in female; p-value: 0.76) and healthy children (4.36 log10 
in male Vs. 4.32 log10 in female; p-value: 0.86). Bacterial loads of specific 
serotypes/serogroups were higher in ARI cases than healthy children in all 
detected serotypes (Figure 3).   Serotypes 14, 19F, 23F, 6A/6B had higher 
median bacterial load than other serotypes in ARI cases while serotypes 14, 
19F, 23A, 23F had higher load in healthy children. The bacterial load of 
serotype 6C/6D was found to be lower than other common serotypes in ARI 
cases.  
Serotype/serogroup specific bacterial load was significantly higher in vaccine 
serotypes. When we compared the bacterial load of vaccine specific 
serotypes and non-vaccine serotypes, the load was higher in vaccine 
serotypes both in ARI cases: 6.61 log10 in vaccine serotypes and 5.51 log10 
in non-vaccine serotypes (P<0.0001), and in healthy children: 4.68 log10 in 
vaccine serotypes and 3.81 log10 in non-vaccine serotypes (P=0.0001). 
 
Correlation between bacterial load of serotypes and their prevalence  
Serotype/serogroup specific bacterial load was positively correlated with 
serotype/serogroup prevalence. Serotype/serogroup specific bacterial load of 
individual NPA samples from ARI cases and healthy children were plotted 
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against the prevalence of individual serotype/serogroup (i.e., proportion of the 
serotypes/serogroups in carriage positive samples). We found that the 
serotype/serogroup specific bacterial load had positive correlation with its 
prevalence, both in ARI cases (Spearman’s rho = 0.44, n=186, P<0.0001) and 
healthy children (Spearman’s rho = 0.41, n=115, P<0.0001) (Figure 4).  
 
Co-colonization with multiple serotypes  
Co-colonization of multiple serotypes of pneumococci was associated with 
ARI.  Co-colonization of multiple-serotypes was detected in 18.5% (n=36/194) 
in ARI cases and 7.1% (n=10/140) in healthy children (OR 2.96, 95%CI 1.41-
6.19; P=0.004). When adjusted for age, sex and daycare, the adjusted odds 
ratio (aOR) was 2.92 (95%CI 1.27-6.71; P=0.012). Co-colonization of 
serotypes 19F and 11, 19F and 15B/15C, 23F and 6A/6B occurred more 
frequently in ARI cases. We observed none of the serotypes involved in co-
colonization were 19A or 35B (Figure 5). Co-colonization of pneumococcus 
occurred in 18.56% (18/97) of ARI cases when pre-hospital antibiotics had 
been used and 38.71% (12/31) when no antibiotics were used (P=0.002) 
[Unknown antibiotic status in 9.09% (6/66) of ARI cases]. The prevalence of 
co-colonization was found to be higher 32.5% (13/40) in age group of less 
than 6 months of age than 14.94% (23/154) in age group of 6 or more than 6 
months of age in ARI cases (P=0.01). But, we did not find any such difference 
in healthy children among these age groups, 0% (0/22) versus 7.04% 
(10/142) (P=0.60).   
 
One serotype/serogroup dominated the other serotype/serogroups in co-
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colonization. In co-colonization, the serotype/serogroup specific bacterial load 
was 2.45 log10 higher in the dominant serotypes than the subdominant 
serotypes in ARI cases, while it was 2.04 log10 higher in healthy children 
(Figure 6). The dominant serotype was a vaccine serotype in 100% (10/10) of 
co-colonization in healthy children (P=0.003); while it was vaccine serotypes 
only in 72.22% (26/36) of co-colonization in ARI cases (P=0.76).  The median 
total bacterial load was higher, 4.48 log10 versus 4.31 log10 (P=0.03), when 
co-colonization of multiple serotypes was present as compared to single 
serotype colonization in healthy children; however, no significant difference 
















Our data suggest two major findings. First, a positive correlation of 
serotype/serogroup specific bacterial load with prevalence of 
serotypes/serogroups, which may help to understand why some serotypes of 
pneumococcus are successful for colonization and maintenance of the 
carriage for longer time.  The second finding, an association of co-colonization 
of multiple serotypes with acute respiratory infections in children may infer a 
role of multiple serotypes of pneumococci in pathogenesis of ARI in children. 
Both of these findings are novel in pneumococcal pathogenesis and 
epidemiology in humans.  
 
It is known that the prevalence of serotypes is inversely correlated with their 
serotype specific invasiveness [5]. It is found that some serotypes/serogroups: 
1, 4, 5, 7F are more invasive but less prevalent in the nasopharynx than other 
serotypes/serogroups: 6A, 6B, 19F, 23F, which are more prevalent but less 
invasive [5]. Contributing factors for this inverse relationship of prevalence 
and invasiveness remains to be fully explained. It is found that colonizing 
serotypes: 19F, 6A, 6B, 23F have higher serotype specific rates of acquisition 
of colonization and longer duration of carriage than invasive serotypes: 1, 4, 
5, 7F in children [6,7].  This shows that the colonizing serotypes are more 
capable to colonize and maintain the carriage than invasive serotypes. In this 
regard, our finding of positive correlation of serotype/serogroup specific 
bacterial load with prevalence of serotype/serogroup may explain that the 
higher numbers of bacteria in the nasopharynx may help them to transmit 
from one host to other, so that they have higher chance of colonization, and 
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their ability to grow in number may help to maintain the carriage for longer 
time against the normal mucosal clearance of the host.  
 
Some in vitro studies show that serotype specific growth of pneumococcus is 
positively correlated with prevalence of the serotype [8,9]. Hathaway et al 
found that high carriage prevalence serotypes (6B, 9V, 19F, 23F) can produce 
their capsules that are less metabolically demanding, and they can grow even 
in nutritionally poor environment [9].  These in vitro findings match with our in 
vivo findings of high bacterial load of common serotypes/serogroups and their 
correlation with prevalence. Less prevalent but more invasive serotypes are 
characterized by poor growth, longer lag phase in bacterial growth [21], 
thinner capsule size and more prone to be killed by neutrophils than high 
prevalence serotypes [8].  
 
We found the occurrence of co-colonization with multiple serotypes of 
pneumococcus was twice as common in hospitalized ARI cases as in healthy 
children. This is the first time to our knowledge that such an association of co-
colonization of multiple serotypes of pneumococci with ARI is reported. 
Although prevalence of co-colonization has been reported to occur from 1.3% 
to 39% in children by using different methods in various settings [11-15], none 
has reported an association with a clinical outcome. Non-vaccine serotypes 
such as 19A and 35B, which have emerged after the introduction of PCV7 
vaccine [3,4], were not detected in co-colonization both in ARI cases and 
healthy children in our study. Although the number of children with co-
colonization was relatively small, our data discourage the “unmasking 
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phenomena” for emergence of non-vaccine serotypes [22]. The potential role 
of co-colonization in the emergence of 19A due to serotype replacement is 
partly explained by capsule switching phenomenon at the capsular locus by 
recombination [23,24]. As pneumococcus is highly recombinogenic and 
transformable bacteria, probability is high for genetic exchange when two or 
more pneumococcal serotypes inhabit at the same time in the nasopharynx 
[10]. This is true for evolution of not only vaccine-escape serotypes but also 
for the antibiotic resistant serotypes [24]. When multiple serotypes co-
colonize, the genetic reservoir expands so called “Supragenome” will advance 
the microevolution of the pathogen and allow continued survival by evasion of 
serotype-specific immune response and adaptation by genetic change, which 
is demonstrated by the co-colonization of penicillin sensitive and penicillin 
resistance pneumococci at the same time [25]. Besides, it is found that in 
mouse model, pneumococci form a biofilm in the nasopharynx when multiple 
strains are present.  The transformation efficiency becomes very high in the 
biofilm with multiple serotypes, so that the antibiotic resistance can easily be 
spread among the serotypes. Hence, co-colonization of multiple serotypes 
confers the development of supra-virulence and fitness in the pathogen for 
survival in the harsh environment of host [26]. 
 
We have further demonstrated the dominance of one serotype over the other 
in bacterial load when co-colonization is present. This difference in 
pneumococcal load among serotypes/serogroups in a co-colonization may 
suggest that there may be a competition among the serotypes for their growth 
due to limited nutrients and space. In mouse model, intra-species competition 
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among pneumococci is demonstrated and found mediated by bacteriocin 
[27,28]. Epidemiological models also suggest the existence of competition 
among serotypes for initiation and persistence of colonization in children 
[16,17]. A study with mathematical modeling shows that direct (physical) 
competition and indirect (antibody mediated) competition do exit among the 
serotypes of pneumococcus in co-colonization [29]. We considered the 100 
fold higher bacterial load, which we found in the dominant serotype, is due to 
direct competition as naturally acquired immune response due to colonization 
lasts for a short duration in unvaccinated young children. This is consistent 
with the finding of the mathematical modeling [29].  
 
This study has limitations. Due to logistic problems, we were unable to bring 
all nasopharyngeal samples to Nagasaki from Vietnam for DNA extraction and 
nanofluidic real-time PCR.  First, we screened all the samples by culture, and 
only samples that grew alpha hemolytic colonies and Optochin sensitive 
isolates were brought to Nagasaki for molecular assays. It may have 
decreased the overall sensitivity of detection of pneumococcus and carriage 
rate. Minimum level of detection of the nanofluidic real-time PCR was 30-300 
copies per reaction; other limitations of the nanofluidic real-time PCR have 
been described elsewhere [20]. 
 
In conclusion, this study showed a positive correlation of serotype/serogroup 
specific bacterial load with serotype/serogroup prevalence of pneumococcus 
in children. Higher bacterial load of a serotype in the nasopharynx might be an 
attributing factor for higher transmission of the serotype. The association of 
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multiple serotypes of pneumococcus with ARI showed its link with increased 
pathogenicity, and dominance of one serotype over the other might infer the 
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Figure 1. Participants recruited into the study, and their nasopharyngeal 
samples. Half of the aliquot of nasopharyngeal samples were cultured 
overnight in 5% sheep blood agar with 5% CO2 at 37°C. DNA was extracted 
directly from the other half of the aliquot of the nasopharyngeal samples which 
yielded alpha hemolytic colonies and positive Optochin test. DNA was 
subjected to lytA PCR to confirm pneumococcus; and lytA positive samples 












Figure 2. Distribution of serotypes/serogroups of pneumococcus in ARI cases 
and healthy children. Thirteen different serotypes/serogroups were detected; 
DNA samples which were positive for lytA (pneumococcus positive), but 
negative for tested 29 serotypes/serogroups were assigned as non-typeable 
(NT). Prevalence of each serotype/serogroup was calculated as proportion of 
total number of a serotype/serogroup to the total number of the lytA positive 
samples. Serotype/serogroup of ARI cases and healthy children were plotted 
in red and blue respectively. Proportion of serotype/serogroup covered by 13-













Future plan and its rationale 
 
Antibiotic resistance in Pneumococcus has dramatically increased in past 
three decades and now become a global health problem [1,2].  Although 
antibiotic resistance is determined by culture and sensitivity conventionally, it 
is less sensitive and tedious procedure; and it is also not available commonly 
in resource-limited countries. Pneumococcus has more than 90 serotypes, 
which have variable capacity to cause diseases and develop antibiotic 
resistance [3-5]. Moreover, the distributions of serotypes vary both 
geographically and temporally; therefore, to determine antibiotic resistance at 
serotype level is essential to treat and control this common pathogen 
effectively [3,4]. Scientists have developed molecular methods to determine 
the antibiotic resistance patterns in recent years [5-8]; however, these 
methods mostly target for one or two antibiotics and the serotype of the 
bacteria cannot be determined simultaneously. So, it takes more time, effort 
and resources to determine antibiotic resistance and individual serotypes, as 
we need to carry out different sets of experiments. Instead, we would like to 
develop a comprehensive assay, which determine both antibiotic resistance 
and serotypes of individual isolates simultaneously. This comprehensive 
assay will be more convenient, efficient and cost-effective than any other 
assay present at this time.  
 
We would like to develop the comprehensive pneumococcal assay by 
including primers for antibiotic resistance genes in the present nanofluidic 
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real-time PCR system [9], so that we will be able to determine serotypes and 
antibiotic resistance simultaneously. This will give us a powerful tool to 
investigate both vaccine and antibiotic effectiveness in the control of this 
common pathogen. Besides, we hope we will discover many new insights in 
pneumococcal biology as we can explore the interrelationships of different 
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